Table 1.
Baseline characteristics of pediatric Crohn’s disease (CD) patients and health subjects
| Characteristic | Healthy subjects (n = 20) |
All CD (n = 29) |
CD treated with IFX (n = 18) |
P# |
|---|---|---|---|---|
| Age, y, median (IQR) | 12 (11, 13) | 13 (11, 14) | 12 (11, 14) | .859 |
| Male, n (%) | 15 (75.0) | 21 (72.4) | 12 (63.2) | .846 |
| Disease location (ParisL) | ||||
| L2, n (%) | 2 (6.9) | 2 (11.1) | .619 | |
| L3, n (%) | 25 (86.2) | 14 (77.8) | .46 | |
| L4, n (%) | 2 (6.9) | 2 (11.1) | .619 | |
| Blood tests | ||||
| WBC (×109/L), median (IQR) | 12.0 (8.0, 17.8) | 11.9 (8.3, 17.6) | .743 | |
| ESR (mm/h), median (IQR) | 64 (42, 104) | 64 (35, 106) | .852 | |
| PLT (×109/L), median (IQR) | 443 (326, 515) | 464 (434, 527) | .381 | |
| CRP (mg/L), median (IQR) | 41 (15, 56) | 41 (18, 58) | .848 | |
| PCDAI, median (IQR) | 32.5 (20.0, 37.5) | 33.8 (25.6, 39.4) | .475 | |
| Outcome of IFX therapy | ||||
| SR, n (%) | 11 (61.1) | |||
| NSR, n (%) | 7 (38.9) |
#The data were compared by the nonparametric Mann–Whitney test (two groups) or Kruskal–Wallis H test (multiple groups).
CD, Crohn’s disease; IFX, infliximab; SR, sustained response; NSR, non-sustained response; WBC, white blood cells; ESR, erythrocyte sedimentation rate; PLT, platelets; CRP, C-reactive protein; PCDAI, Pediatric Crohn’s Disease Activity Index.